These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 33609416)

  • 1. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
    Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
    J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review.
    Vagnozzi E; Bruni M; Esposito M; Fargnoli MC
    J Dermatolog Treat; 2023 Dec; 34(1):2270091. PubMed ID: 37842732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
    Frew JW; Navrazhina K; Grand D; Sullivan-Whalen M; Gilleaudeau P; Garcet S; Ungar J; Krueger JG
    J Am Acad Dermatol; 2020 Nov; 83(5):1341-1348. PubMed ID: 32416208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
    Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
    Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.
    Tampouratzi E; Kanni T; Katsantonis J; Douvali T
    F1000Res; 2019; 8():2002. PubMed ID: 33456757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hidradenitis suppurativa with biologic medications.
    Lee RA; Eisen DB
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
    Yen CF; Huang YH; Chi CC
    Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.
    Berman HS; Villa NM; Shi VY; Hsiao JL
    J Dermatolog Treat; 2021 Mar; 32(2):261-263. PubMed ID: 31389737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
    Aarts P; Dudink K; Vossen ARJV; van Straalen KR; Ardon CB; Prens EP; van der Zee HH
    Drugs; 2021 Aug; 81(12):1397-1410. PubMed ID: 34283386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
    Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
    Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
    Maarouf M; Clark AK; Lee DE; Shi VY
    J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.
    Zouboulis CC
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1015-26. PubMed ID: 27531618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.
    Molinelli E; Gioacchini H; Sapigni C; Diotallevi F; Brisigotti V; Rizzetto G; Offidani A; Simonetti O
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of hidradenitis suppurativa with infliximab in a patient who failed to respond to etanercept.
    Poulin Y
    J Cutan Med Surg; 2009; 13(4):221-5. PubMed ID: 19706231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum.
    Navrazhina K; Frew JW; Grand D; Williams SC; Hur H; Gonzalez J; Garcet S; Krueger JG
    Br J Dermatol; 2022 Aug; 187(2):223-233. PubMed ID: 35191018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics for hidradenitis suppurativa: an update.
    Włodarek K; Ponikowska M; Matusiak Ł; Szepietowski JC
    Immunotherapy; 2019 Jan; 11(1):45-59. PubMed ID: 30702012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in biologic and small molecule therapies for hidradenitis suppurativa.
    Chen SX; Greif C; Gibson RS; Porter ML; Kimball AB
    Expert Opin Pharmacother; 2022 Jun; 23(8):959-978. PubMed ID: 35470765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimekizumab for the treatment of hidradenitis suppurativa.
    Shams RB; Sayed CJ
    Immunotherapy; 2024; 16(16-17):1005-1013. PubMed ID: 39297706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
    Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.